Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer

  • Authors:
    • Nobuo Matsunaga
    • Nobuya Yamada
    • Masaichi Ohira
    • Akiko Tachimori
    • Yukio Nishiguchi
    • Hiroji Nishino
    • Syuichi Seki
    • Kosei Hirakawa
  • View Affiliations

  • Published online on: January 1, 2004     https://doi.org/10.3892/or.11.1.167
  • Pages: 167-171
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Liver metastasis is a major contributor to mortality in patients with colorectal cancer. Hence, it is essential to establish preventive therapy to control liver metastasis. Recently, it has become widely accepted that cyclooxygenase (COX)-2 inhibitors possess anti-cancer activity for various types of tumor, especially colorectal. The clinical application of COX-2 inhibitors may therefore be beneficial. In this study, we have developed a combined treatment with a selective COX-2 inhibitor and fluorinated pyrimidines for liver metastasis of colorectal cancer, and examined the effect of these agents on proliferation and invasion of a highly metastatic human colon cancer cell line, LM-H3. The COX-2 inhibitor etodolac was found to inhibit cell invasion of LM-H3. 5-Fluorouracil (5-FU) inhibited proliferation of this line in vitro. Etodolac did not increase the inhibitory effect of 5-FU on cell proliferation. We also examined the inhibitory effect of etodolac and UFT, belonging to the fluorinated pyrimidines, on liver metastasis by using a liver metastatic model in the nude mouse. Combined treatment with etodolac and UFT markedly reduced liver metastasis. Serious side effects were not observed. In conclusion, combined treatment with etodolac and UFT might be a promising preventive therapy for liver metastasis of colon cancer.

Related Articles

Journal Cover

January 2004
Volume 11 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Matsunaga N, Yamada N, Ohira M, Tachimori A, Nishiguchi Y, Nishino H, Seki S and Hirakawa K: Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. Oncol Rep 11: 167-171, 2004
APA
Matsunaga, N., Yamada, N., Ohira, M., Tachimori, A., Nishiguchi, Y., Nishino, H. ... Hirakawa, K. (2004). Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. Oncology Reports, 11, 167-171. https://doi.org/10.3892/or.11.1.167
MLA
Matsunaga, N., Yamada, N., Ohira, M., Tachimori, A., Nishiguchi, Y., Nishino, H., Seki, S., Hirakawa, K."Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer". Oncology Reports 11.1 (2004): 167-171.
Chicago
Matsunaga, N., Yamada, N., Ohira, M., Tachimori, A., Nishiguchi, Y., Nishino, H., Seki, S., Hirakawa, K."Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer". Oncology Reports 11, no. 1 (2004): 167-171. https://doi.org/10.3892/or.11.1.167